Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01337297
Other study ID # CEP-UFES 296/10
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received April 14, 2011
Last updated December 23, 2013
Start date June 2011
Est. completion date May 2013

Study information

Verified date December 2013
Source Federal University of Espirito Santo
Contact n/a
Is FDA regulated No
Health authority Brazil: Ethics Committee
Study type Interventional

Clinical Trial Summary

The use of crack-cocaine is growing at alarming rate in our country and it is absolutely worrisome the fast establishment of addiction to it. Its immediate effects, that are intense and extremely fleeting, increase dramatically the probability of this drug to be consumed again, settling quickly down the loss of control and the compulsive use, turning the effects of this drug highly addictive. Parallel to this process, brain damages are quickly established, progressing to severe impairments of frontal functions, leading to the lack of cognitive control that feeds back and aggravates the dependence, and hampers any therapeutic approach. The existing treatments have not proved to be satisfactory yet. Thus, considering that a new modality of treatment, based on the neuromodulation induced by noninvasive brain stimulation, has been useful in treating various neuropsychiatric conditions, this study will examine the potential beneficial effects of repeated transcranial Direct Current Stimulation over the left dorsolateral prefrontal cortex in the treatment of crack-cocaine addiction.


Description:

Forty subjects between 18 and 60 years old, both genders, with a diagnosis of dependence on crack-cocaine, evaluated for the first time at the Center for Psychosocial Care for Alcohol and Other Drugs (CAPS-AD, in Portuguese) in the municipality of Serra, ES, Brazil, will be invited to participate in this study. After triage, following the inclusion and exclusion criteria, they will be informed in details about the experimental protocol and, if they agree to participate, it will be required to sign an Informed Consent. It Will be applied a structured anamnesis, made a psychiatric clinical and physical examination. The treatment will be started with regular medications for abstinence and comorbidities and psychosocial approaches usually done in the CAPS-AD. After selected they will be referred to the Laboratory of Cognitive Science and Neuropsychopharmacology of the Postgraduate Program in Physiological Sciences from Health Sciences Center of Federal University of EspĂ­rito Santo where they will be semi-randomly (matched for age, gender and sociodemographic characteristics) distributed into two different groups: (A) sham-tDCS (n = 20) and (B) active-tDCS (n = 20); and they will follow for 10 applications in daily sessions, excepting on weekends, of transcranial direct current stimulation (tDCS, 5 x 7 cm2, 2 mA, 20 min) over the left dorsolateral prefrontal cortex or sham procedure. Event-related potentials (ERP) will be recorded before, during and after brain stimulation or sham procedure under random presentation of three related images and three non-related images to crack use. The compulsive behavior will be evaluated before and after the ERP records. Cognitive tests which assess mental function, frontal function, visuospatial and verbal working memory, inhibition, and conflict resolution will be performed. The depression will be assessed during the treatment, and the addicted subjects will be evaluated once a week for four consecutive weeks after a series of applications of sham-tDCS or active-tDCS.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 2013
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- fulfill the criteria for the crack-dependence syndrome, based on criteria of the International Classification of Diseases on its 10th version;

- all users and addicts who make use of crack-cocaine alone or in combination with other drugs (alcohol, nicotine, caffeine, cannabis, etc.), or who have psychiatric comorbidities (anxiety, depression, etc.)

- must be clinically stable and not requiring hospitalization;

- should be clinically suitable for the treatment proposed in this study;

- need to be able to read, write and speak Portuguese

Exclusion Criteria:

- should not present current or past illnesses that may be aggravated during treatment;

- may not show abnormalities in laboratory tests which suggest a deterioration of its physical condition for participation in the study;

- individuals who have some metal in the brain or skull (chips, fragments, pins, etc. - except titanium);

- history of epilepsy, severe brain trauma, cochlear implant, cardiac pacemaker or intracardiac metal apparatus);

- pregnants.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Intervention

Device:
transcranial Direct Current Stimulation
transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).

Locations

Country Name City State
Brazil Laboratory of Cognitive Sciences and Neuropsychopharmacology, Post-Graduation Program in Physiologycal Sciences, Health Sciences Center, Federal University of Espírito Santo Vitória Espírito Santo

Sponsors (3)

Lead Sponsor Collaborator
Federal University of Espirito Santo Harvard University, University of Göttingen

Country where clinical trial is conducted

Brazil, 

References & Publications (10)

Aharonovich E, Hasin DS, Brooks AC, Liu X, Bisaga A, Nunes EV. Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug Alcohol Depend. 2006 Feb 28;81(3):313-22. Epub 2005 Sep 19. — View Citation

Aharonovich E, Nunes E, Hasin D. Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. Drug Alcohol Depend. 2003 Aug 20;71(2):207-11. — View Citation

Boggio PS, Rigonatti SP, Ribeiro RB, Myczkowski ML, Nitsche MA, Pascual-Leone A, Fregni F. A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int J Neuropsychopharmacol. 2008 Mar;11(2):249-54. Epub 2007 Jun 11. — View Citation

Boggio PS, Sultani N, Fecteau S, Merabet L, Mecca T, Pascual-Leone A, Basaglia A, Fregni F. Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: a double-blind, sham-controlled study. Drug Alcohol Depend. 2008 Jan 1;92(1-3):55-60. Epub 2007 Jul 19. — View Citation

Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000 Dec 12;55(11):1621-6. — View Citation

Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. — View Citation

Franco GM. [The cognitive potential in normal adults]. Arq Neuropsiquiatr. 2001 Jun;59(2-A):198-200. Portuguese. — View Citation

Fregni F, Boggio PS, Nitsche M, Bermpohl F, Antal A, Feredoes E, Marcolin MA, Rigonatti SP, Silva MT, Paulus W, Pascual-Leone A. Anodal transcranial direct current stimulation of prefrontal cortex enhances working memory. Exp Brain Res. 2005 Sep;166(1):23-30. Epub 2005 Jul 6. — View Citation

HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62. — View Citation

Nitsche MA, Cohen LG, Wassermann EM, Priori A, Lang N, Antal A, Paulus W, Hummel F, Boggio PS, Fregni F, Pascual-Leone A. Transcranial direct current stimulation: State of the art 2008. Brain Stimul. 2008 Jul;1(3):206-23. doi: 10.1016/j.brs.2008.06.004. Epub 2008 Jul 1. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Abstinence abstinence to the use of crack-cocaine up to 3 months after the completion of two-weeks of treatment sessions with active-tDCS or sham-tDCS. Two days after the end of tDCS treatment (one session every other day, 5 sessions), that is, on the 12nd day from the beginning. No
Secondary Intensity of the Urge to the Use of Crack-cocaine The intensity of craving will be examined by a short scale, the Brief Cocaine Craving Questionnaire. before and after ERP in two weekly sessions over two weeks No
Secondary Event Related Potentials Event Related Potentials (ERPs) elicited by random presentation of three related images and three non-related images to crack use every Monday and Friday over the two-weeks period of active-tDCS or sham-tDCS. twice a week over two consecutive weeks during the treatment No
Secondary Cognitive Tests Cognitive tests are comprised by frontal assessment battery (FAB), Mini-Mental Status Examination (MMSE), verbal n-back task, visuospatial n-back task, go/no-go test. Before the first experimental session, in the middle of the protocol and two days after the last experimental session No
Secondary State of Depression It will be applied Hamilton Scale for Depression, a structured multiple choice questionnaire used to assess the severity of the symptoms of depression. It will be applied with cognitive tests. Before the first experimental session, in the middle of the treatment and after the last experimental session. No
See also
  Status Clinical Trial Phase
Recruiting NCT04111549 - GOALS Cognitive Training Delivered to Aging Veterans in Person or Via Telehealth N/A
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Enrolling by invitation NCT05017779 - A Hybrid Effectiveness-implementation Trial of a High School-based Executive Function Treatment for Autistic Youth N/A
Terminated NCT02416193 - Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D) Phase 2
Completed NCT02613936 - Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury N/A
Recruiting NCT05874791 - Executive Control Training for Adolescents With ADHD: A Randomized Controlled Effectiveness Trial N/A
Recruiting NCT04465708 - HOPS Study: A Conceptual Replication N/A
Active, not recruiting NCT05131659 - Intervention-Induced Plasticity of Flexibility and Learning Mechanisms in ASD N/A
Active, not recruiting NCT04121650 - Executive Function and Symptom Reduction in Youth Receiving Home-based Treatment With Collaborative Problem Solving
Completed NCT04221841 - Executive Functions and Reinforcement Sensitivity in Women With Obsessive Compulsive Symptoms
Completed NCT03285347 - Effect of Computer-based Cognitive Training on Attention and Executive Functions in Patients With Parkinson's Disease N/A
Completed NCT03490110 - Brain Markers of Improvements in Cognitive Functioning N/A
Completed NCT03073122 - The Boston Circulatory Arrest Study: Antecedents and Correlates of Well-Being in Adults With Congenital Heart Disease
Completed NCT03958487 - An Executive/Monitoring Treatment Protocol on Everyday Life Activities N/A
Completed NCT02091284 - Bilateral Prefrontal Modulation in Alcoholism N/A
Completed NCT02091167 - Bilateral Prefrontal Modulation in Crack-cocaine Addiction Phase 2
Completed NCT01730261 - Online Emotional Regulation Group Treatment Phase 1
Completed NCT00271596 - Citalopram to Enhance Cognition in HD Phase 2
Active, not recruiting NCT04108728 - Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers ( NEUROPSY-HEU ) N/A
Active, not recruiting NCT04105530 - Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) N/A